[Raloxifene hydrochloride].
Itabashi
Akira
A
Department of Clinical Laboratory Medicine, Saitama Medical School.
D001161:Arteriosclerosis / Q000517:prevention & control; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000517:prevention & control; D001943:Breast Neoplasms / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000517:prevention & control; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D004965:Estrogen Antagonists; D004967:Estrogens / Q000819:agonists; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000494:pharmacology* / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology* / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000517:prevention & control
D008078:Cholesterol, LDL; D004965:Estrogen Antagonists; D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride